Citi Starts Intellia Therapeutics (NTLA) at Sell
Tweet
Share
E-mailGet Alerts NTLA Hot Sheet
Price: $12.84 +3.22%
Rating Summary:
23 Buy, 9 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
23 Buy, 9 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Citi analyst David Lebowitz initiates coverage on Intellia Therapeutics (NASDAQ: NTLA) with a Sell rating and a price target of $50.00.
For an analyst ratings summary and ratings history on Intellia Therapeutics click here. For more ratings news on Intellia Therapeutics click here.
Shares of Intellia Therapeutics closed at $60.06 yesterday.
You May Also Be Interested In
- DA Davidson Starts Everus (ECG) at Buy
- TD Cowen Assumes Iovanace Biotherapeutics (IOVA) at Buy
- Keefe, Bruyette & Woods Resumes Toronto-Dominion Bank (TD:CN) (TD) at Market Perform
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
